Results 171 to 180 of about 776,039 (330)

Accuracy of patient dose estimation in cone beam computed tomography in breast irradiation by size‐specific dose estimates with position correction

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract This study aims to investigate the effects of the position correction of size‐specific dose estimates (SSDE) on patient dose estimation in cone beam computed tomography (CBCT). The relationship between the phantom position and absorbed dose in the right breast was studied using optically stimulated luminescence dosimeters and a simulated human
Hiroyuki Ueno, Kosuke Matsubara, Sayuri Bou, Masato Hizume   +3 more
wiley   +1 more source

Comparative activity of dimethyl fumarate derivative IDMF in three models relevant to multiple sclerosis and psoriasis

FEBS Open Bio, EarlyView.
IDMF is a derivative of dimethyl fumarate (DMF) with a unique therapeutic potential at the intersection of psoriasis and multiple sclerosis. Here, we demonstrate that it compares favorably with DMF and its other derivatives, such as Diroximel, in the zebrafish, microglia, and lymphocyte models.
Yulin He, Guiyi Gong, Geovani Quijas, Simon Ming‐Yuen Lee, Ratan K. Chaudhuri, Krzysztof Bojanowski   +5 more
wiley   +1 more source

Evaluation of patient doses for routine digital radiography procedures toward establishing an institutional diagnostic reference levels: A case study in Sri Lanka

Journal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract The present study was conducted as part of a comprehensive work to establish National Diagnostic Reference Levels (NDRLs) in Sri Lanka for the first time. DRLs can be used as an effective optimization tool for identifying unusually high or low patient doses during X‐ray examinations.
Sachith Welarathna, Sivakumar Velautham, Mihira Wanninayake, Sivananthan Sarasanandarajah   +3 more
wiley   +1 more source

Pharmacological effects of osimertinib on a chicken chorioallantoic membrane xenograft model with the EGFR exon‐19‐deleted advanced NSCLC mutation

FEBS Open Bio, EarlyView.
Osimertinib reduces angiogenesis and PDL1 expression in in ovo tumors, transforming them into ‘cold tumors’ with lower immune activity. Anatomopathological and transcriptomic analyses highlight its therapeutic impact on tumor biology. This study underscores osimertinib's potential to reshape the tumor microenvironment and provides insights into its ...
David Barthélémy, Arnaud Vigneron, Xavier Rousset, Jérome Guitton, Emmanuel Grolleau, Margaux Raffin, Julie Balandier, Gaëlle Lescuyer, Mathilde Bardou, Florence Geiguer, Sébastien Couraud, Claire Bardel, Jean Viallet, Nazim Benzerdjeb, Léa Payen   +14 more
wiley   +1 more source

DrugCLIP: Contrastive Drug-Disease Interaction For Drug Repurposing [PDF]

arXiv
Bringing a novel drug from the original idea to market typically requires more than ten years and billions of dollars. To alleviate the heavy burden, a natural idea is to reuse the approved drug to treat new diseases. The process is also known as drug repurposing or drug repositioning.
arxiv  

Australia makes concessions on drug approvals after US pressure [PDF]

, 2004
Bob Burton
openalex   +1 more source

The Two Towers: Quest for Drugs from Discovery to Approval [PDF]

, 2004
Ron Cohen, Patrick J. Potter
openalex   +1 more source

A potential tumor suppressor role of PLK2 in glioblastoma

FEBS Open Bio, EarlyView.
PLK2 was consistently downregulated in GBM tissues. Overexpression of PLK2 in GBM cell lines U87MG and U251 reduced their tumorigenic potential and enhanced cell cycle arrest and apoptosis. Suggesting that PLK2 overexpression could potentially be leveraged as a therapeutic strategy to inhibit tumor progression and enhance apoptosis, providing new ...
Xiangping Xia, Peirui Wang, Hua Xiao, Qishan Ran, Yan Li, Shengtao Yao   +5 more
wiley   +1 more source

Identification of inhibitors of the Salmonella FraB deglycase, a drug target

FEBS Open Bio, EarlyView.
A high‐throughput screen was used to identify inhibitors of Salmonella FraB, a drug target. Characterization of top hits (identified after an additional counter screen) revealed that some triazolidines, thiadiazolidines, and triazolothiadiazoles are mixed‐type inhibitors of FraB.
Jamison D. Law, Yuan Gao, Sravya Kovvali, Pankajavalli Thirugnanasambantham, Vicki H. Wysocki, Brian M. M. Ahmer, Venkat Gopalan   +6 more
wiley   +1 more source

DeepCRE: Transforming Drug R&D via AI-Driven Cross-drug Response Evaluation [PDF]

arXiv
The fields of therapeutic application and drug research and development (R&D) both face substantial challenges, i.e., the therapeutic domain calls for more treatment alternatives, while numerous promising pre-clinical drugs have failed in clinical trials.
arxiv